Miconazole mucoadhesive tablets: A novel delivery system

José A. Vazquez; Jack D. Sobel

doi:10.1093/cid/cis205

Miconazole mucoadhesive tablets: A novel delivery system

José A. Vazquez, Jack D. Sobel

Infectious Disease

Research output: Contribution to journal › Review article

19 Scopus citations

Abstract

Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.

Original language	English (US)
Pages (from-to)	1480-1484
Number of pages	5
Journal	Clinical Infectious Diseases
Volume	54
Issue number	10
DOIs	https://doi.org/10.1093/cid/cis205
State	Published - May 15 2012

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cis205

Fingerprint Dive into the research topics of 'Miconazole mucoadhesive tablets: A novel delivery system'. Together they form a unique fingerprint.

Cite this

Vazquez, J. A., & Sobel, J. D. (2012). Miconazole mucoadhesive tablets: A novel delivery system. Clinical Infectious Diseases, 54(10), 1480-1484. https://doi.org/10.1093/cid/cis205

@article{1adea2fca33b47fdb35cdf91480b622a,

title = "Miconazole mucoadhesive tablets: A novel delivery system",

abstract = "Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.",

author = "Vazquez, {Jos{\'e} A.} and Sobel, {Jack D.}",

year = "2012",

month = may,

day = "15",

doi = "10.1093/cid/cis205",

language = "English (US)",

volume = "54",

pages = "1480--1484",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

number = "10",

}

TY - JOUR

T1 - Miconazole mucoadhesive tablets

T2 - A novel delivery system

AU - Vazquez, José A.

AU - Sobel, Jack D.

PY - 2012/5/15

Y1 - 2012/5/15

N2 - Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.

AB - Oropharyngeal candidiasis (OPC) is among the most common opportunistic infections observed in persons infected with human immunodeficiency virus. A once-daily miconazole 50 mg mucoadhesive buccal tablet (MBT) is a novel delivery system with potent in vitro activity against many Candida species, including some that may be resistant to other azoles. MBT, although more expensive, offers an effective, safe, and well-tolerated topical treatment option for OPC that is administered as a convenient once-daily dose.

UR - http://www.scopus.com/inward/record.url?scp=84860251686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860251686&partnerID=8YFLogxK

U2 - 10.1093/cid/cis205

DO - 10.1093/cid/cis205

M3 - Review article

C2 - 22495075

AN - SCOPUS:84860251686

VL - 54

SP - 1480

EP - 1484

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 10

ER -